Unequivocal randomized trial data show that PSA velocity does not benefit decision making in localized prostate cancer. A recent paper suggests that the literature is wrong and that PSA velocity does predict aggressive disease; however, the study design is flawed and the key claim seems to be based on a typographical error.
